Emerging treatment options for extraintestinal manifestations in IBD
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging treatment options for extraintestinal manifestations in IBD
Authors
Keywords
-
Journal
GUT
Volume -, Issue -, Pages gutjnl-2020-322129
Publisher
BMJ
Online
2020-08-27
DOI
10.1136/gutjnl-2020-322129
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inflammatory cutaneous lesions in inflammatory bowel disease treated with Vedolizumab or Ustekinumab: an ECCO CONFER multicentre case series
- (2020) F M Phillips et al. Journal of Crohns & Colitis
- Anti interleukin 12/23 in the treatment of erythema nodosum and Crohn disease: A case report
- (2019) Rocco Spagnuolo et al. Dermatologic Therapy
- Successful Treatment of Pyoderma Gangrenosum with Concomitant Tofacitinib and Infliximab
- (2019) Martin H Gregory et al. INFLAMMATORY BOWEL DISEASES
- Incidence of Immune-mediated Inflammatory Diseases Among Patients With Inflammatory Bowel Diseases in Denmark
- (2019) Johan Burisch et al. Clinical Gastroenterology and Hepatology
- Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review
- (2019) Thomas Chateau et al. Journal of Crohns & Colitis
- Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials
- (2018) Brian G Feagan et al. Journal of Crohns & Colitis
- Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis
- (2018) Atul Deodhar et al. Arthritis & Rheumatology
- Tofacitinib for the Treatment of Pyoderma Gangrenosum
- (2018) Bharati Kochar et al. Clinical Gastroenterology and Hepatology
- The Pathogenesis of Extraintestinal Manifestations: Implications for IBD research, diagnosis and therapy
- (2018) C R H Hedin et al. Journal of Crohns & Colitis
- Refractory Pyoderma Gangrenosum in a Patient With Crohn′s Disease: Complete Response to Ustekinumab
- (2018) Gonçalo Nunes et al. Journal of Crohns & Colitis
- Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab — The GO-EASY Study
- (2018) Rianne E. van Bentum et al. JOURNAL OF RHEUMATOLOGY
- Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial
- (2018) Désirée van der Heijde et al. LANCET
- Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
- (2018) Philip Mease et al. LANCET
- Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)
- (2017) Silvio Danese et al. GUT
- Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
- (2017) Julian Panés et al. GUT
- Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study
- (2017) Stephan R. Vavricka et al. INFLAMMATORY BOWEL DISEASES
- Expression Patterns of TNFα, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease
- (2017) Stephan R Vavricka et al. Journal of Crohns & Colitis
- Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease
- (2017) Megan Hohenberger et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease
- (2017) Thomas Greuter et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
- (2017) Philip Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
- (2017) Dafna Gladman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)
- (2016) Arthur Kavanaugh et al. ANNALS OF THE RHEUMATIC DISEASES
- Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
- (2016) A Kavanaugh et al. ANNALS OF THE RHEUMATIC DISEASES
- Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
- (2016) R Westhovens et al. ANNALS OF THE RHEUMATIC DISEASES
- Concomitant hidradenitis suppurativa and pyostomatitis vegetans in silent ulcerative colitis successfully treated with golimumab
- (2016) Antonio Tursi DIGESTIVE AND LIVER DISEASE
- Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
- (2016) M. Rudwaleit et al. ARTHRITIS CARE & RESEARCH
- Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
- (2015) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Extraintestinal Manifestations of Inflammatory Bowel Disease
- (2015) Stephan R. Vavricka et al. INFLAMMATORY BOWEL DISEASES
- The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease
- (2015) Marcus Harbord et al. Journal of Crohns & Colitis
- Optimising the Inflammatory Bowel Disease Unit to Improve Quality of Care: Expert Recommendations: Table 1.
- (2015) Edouard Louis et al. Journal of Crohns & Colitis
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
- (2015) Hervé Bachelez et al. LANCET
- A Randomized, Double-Blind, Placebo-Controlled, Sixteen-Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis
- (2015) J. Sieper et al. Arthritis & Rheumatology
- Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)
- (2014) Denis Poddubnyy et al. ANNALS OF THE RHEUMATIC DISEASES
- Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials
- (2014) Arthur Kavanaugh et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib versus Methotrexate in Rheumatoid Arthritis
- (2014) Eun Bong Lee et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
- (2013) Joel Kremer et al. ANNALS OF INTERNAL MEDICINE
- Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
- (2013) R Landewé et al. ANNALS OF THE RHEUMATIC DISEASES
- Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
- (2013) P J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study
- (2013) Désirée van der Heijde et al. ARTHRITIS AND RHEUMATISM
- Characteristics and Treatment of Pyoderma Gangrenosum in Inflammatory Bowel Disease
- (2013) F. Argüelles-Arias et al. DIGESTIVE DISEASES AND SCIENCES
- Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
- (2013) Iain B McInnes et al. LANCET
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
- (2013) Gerd R Burmester et al. LANCET
- Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease
- (2013) Manuel Barreiro-de-Acosta et al. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS
- Treatment of Extraintestinal Manifestations in Inflammatory Bowel Disease
- (2012) Peter L. Lakatos et al. DIGESTION
- Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
- (2012) Wolfgang Hueber et al. GUT
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study
- (2011) Yoshiya Tanaka et al. ANNALS OF THE RHEUMATIC DISEASES
- Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohnʼs disease: Results from CARE
- (2011) Robert Löfberg et al. INFLAMMATORY BOWEL DISEASES
- Frequency and Risk Factors for Extraintestinal Manifestations in the Swiss Inflammatory Bowel Disease Cohort
- (2010) Stephan R Vavricka et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study
- (2009) Arthur Kavanaugh et al. ARTHRITIS AND RHEUMATISM
- Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis
- (2009) Paul Emery et al. ARTHRITIS AND RHEUMATISM
- Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
- (2008) J Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Golimumab, a human antibody to tumour necrosis factor given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
- (2008) E C Keystone et al. ANNALS OF THE RHEUMATIC DISEASES
- Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
- (2008) Edward Keystone et al. ARTHRITIS AND RHEUMATISM
- Infliximab for Inflammatory Bowel Disease in Denmark 1999–2005: Clinical Outcome and Follow-Up Evaluation of Malignancy and Mortality
- (2008) Sarah Caspersen et al. Clinical Gastroenterology and Hepatology
- The multidisciplinary team for management of inflammatory bowel diseases
- (2008) C. Ricci et al. DIGESTIVE AND LIVER DISEASE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started